Caricamento...
DDIS-08. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR GLIOBLASTOMA
The epidermal growth factor receptor (EGFR) is altered in nearly 60% of glioblastoma (GBM) tumors, however, EGFR tyrosine kinase inhibitors (TKIs) have failed to improve outcomes for GBM patients. This can be attributed to the inability of conventional EGFR TKIs (e.g., erlotinib, gefitinib, lapatini...
Salvato in:
| Pubblicato in: | Neuro Oncol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216525/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.287 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|